Surgical Science Sweden AB (publ)

LSE:0AAU Stock Report

Market Cap: SEK 8.9b

Surgical Science Sweden Valuation

Is 0AAU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0AAU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 311.37
Fair Value
44.7% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: 0AAU (SEK172.3) is trading below our estimate of fair value (SEK311.37)

Significantly Below Fair Value: 0AAU is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0AAU?

Key metric: As 0AAU is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0AAU. This is calculated by dividing 0AAU's market cap by their current earnings.
What is 0AAU's PE Ratio?
PE Ratio46x
EarningsSEK 193.34m
Market CapSEK 8.90b

Price to Earnings Ratio vs Peers

How does 0AAU's PE Ratio compare to its peers?

The above table shows the PE ratio for 0AAU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.3x
NIOX NIOX Group
22.8x18.4%UK£250.7m
EKF EKF Diagnostics Holdings
25.2xn/aUK£120.2m
SN. Smith & Nephew
35.6x22.6%UK£8.8b
AMS Advanced Medical Solutions Group
41.5x20.8%UK£461.9m
0AAU Surgical Science Sweden
46x36.1%SEK 8.9b

Price-To-Earnings vs Peers: 0AAU is expensive based on its Price-To-Earnings Ratio (46x) compared to the peer average (31.3x).

Price to Earnings Ratio vs Industry

How does 0AAU's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies8PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0AAU is expensive based on its Price-To-Earnings Ratio (46x) compared to the European Medical Equipment industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0AAU's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0AAU PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46x
Fair PE Ratio47x

Price-To-Earnings vs Fair Ratio: 0AAU is good value based on its Price-To-Earnings Ratio (46x) compared to the estimated Fair Price-To-Earnings Ratio (47x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0AAU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 172.30
SEK 192.17
+11.5%
10.0%SEK 225.00SEK 165.00n/a6
Jan ’26SEK 155.90
SEK 192.17
+23.3%
10.0%SEK 225.00SEK 165.00n/a6
Dec ’25SEK 149.50
SEK 192.17
+28.5%
10.0%SEK 225.00SEK 165.00n/a6
Nov ’25SEK 128.80
SEK 188.17
+46.1%
15.3%SEK 225.00SEK 135.00n/a6
Oct ’25SEK 125.40
SEK 188.17
+50.1%
15.3%SEK 225.00SEK 135.00n/a6
Sep ’25SEK 124.00
SEK 189.00
+52.4%
14.4%SEK 225.00SEK 140.00n/a6
Aug ’25SEK 129.80
SEK 204.00
+57.2%
19.1%SEK 260.00SEK 140.00n/a6
Jul ’25SEK 125.40
SEK 204.00
+62.7%
19.1%SEK 260.00SEK 140.00n/a6
Jun ’25SEK 144.60
SEK 208.17
+44.0%
15.7%SEK 260.00SEK 165.00n/a6
May ’25SEK 157.10
SEK 221.50
+41.0%
13.6%SEK 260.00SEK 165.00n/a6
Apr ’25SEK 151.70
SEK 222.33
+46.6%
13.7%SEK 260.00SEK 165.00n/a6
Mar ’25SEK 155.20
SEK 228.17
+47.0%
9.1%SEK 260.00SEK 200.00n/a6
Feb ’25SEK 178.80
SEK 239.00
+33.7%
11.1%SEK 275.00SEK 200.00n/a6
Jan ’25SEK 189.10
SEK 236.50
+25.1%
13.8%SEK 275.00SEK 180.00SEK 155.906
Dec ’24SEK 173.24
SEK 236.50
+36.5%
13.8%SEK 275.00SEK 180.00SEK 149.506
Nov ’24SEK 128.93
SEK 242.33
+88.0%
12.0%SEK 280.00SEK 195.00SEK 128.806
Oct ’24SEK 150.28
SEK 254.00
+69.0%
14.4%SEK 300.00SEK 195.00SEK 125.405
Sep ’24SEK 163.97
SEK 263.00
+60.4%
9.3%SEK 300.00SEK 235.00SEK 124.005
Aug ’24SEK 236.98
SEK 272.20
+14.9%
10.9%SEK 300.00SEK 233.00SEK 129.805
Jul ’24SEK 241.20
SEK 272.20
+12.9%
10.9%SEK 300.00SEK 233.00SEK 125.405
Jun ’24SEK 230.00
SEK 272.20
+18.3%
10.9%SEK 300.00SEK 233.00SEK 144.605
May ’24SEK 187.08
SEK 233.40
+24.8%
18.6%SEK 290.00SEK 182.00SEK 157.105
Apr ’24SEK 169.22
SEK 232.40
+37.3%
18.9%SEK 290.00SEK 182.00SEK 151.705
Mar ’24SEK 172.73
SEK 236.00
+36.6%
21.4%SEK 290.00SEK 170.00SEK 155.204
Feb ’24SEK 148.70
SEK 239.00
+60.7%
23.1%SEK 305.00SEK 170.00SEK 178.804
Jan ’24SEK 164.97
SEK 239.00
+44.9%
23.1%SEK 305.00SEK 170.00SEK 189.104
Analyst Price Target
Consensus Narrative from 6 Analysts
SEK 189.85
Fair Value
9.2% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 06:27
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Surgical Science Sweden AB (publ) is covered by 5 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Simon JonssonBerenberg
Viktor HögbergDanske Bank
Jonatan AnderssonDNB Markets